These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
300 related articles for article (PubMed ID: 10221288)
21. Algorithm-based treatment of major depression in an outpatient clinic: clinical correlates of response to a specific serotonin reuptake inhibitor and to triiodothyronine augmentation. Agid O; Lerer B Int J Neuropsychopharmacol; 2003 Mar; 6(1):41-9. PubMed ID: 12899735 [TBL] [Abstract][Full Text] [Related]
22. Response to an open trial of a second SSRI in major depression. Joffe RT; Levitt AJ; Sokolov ST; Young LT J Clin Psychiatry; 1996 Mar; 57(3):114-5. PubMed ID: 8617695 [TBL] [Abstract][Full Text] [Related]
23. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. Fava M; Judge R; Hoog SL; Nilsson ME; Koke SC J Clin Psychiatry; 2000 Nov; 61(11):863-7. PubMed ID: 11105740 [TBL] [Abstract][Full Text] [Related]
24. Bupropion sustained release as a smoking cessation treatment in remitted depressed patients maintained on treatment with selective serotonin reuptake inhibitor antidepressants. Chengappa KN; Kambhampati RK; Perkins K; Nigam R; Anderson T; Brar JS; Vemulapalli HK; Atzert R; Key P; Kang JS; Levine J J Clin Psychiatry; 2001 Jul; 62(7):503-8. PubMed ID: 11488359 [TBL] [Abstract][Full Text] [Related]
25. Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday. Rothschild AJ Am J Psychiatry; 1995 Oct; 152(10):1514-6. PubMed ID: 7573593 [TBL] [Abstract][Full Text] [Related]
26. Aripiprazole augmentation in 13 patients with refractory obsessive-compulsive disorder: a case series. Higuma H; Kanehisa M; Maruyama Y; Ishitobi Y; Tanaka Y; Tsuru J; Hanada H; Kodama K; Isogawa K; Akiyoshi J World J Biol Psychiatry; 2012 Jan; 13(1):14-21. PubMed ID: 22256827 [TBL] [Abstract][Full Text] [Related]
27. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. Landén M; Björling G; Agren H; Fahlén T J Clin Psychiatry; 1998 Dec; 59(12):664-8. PubMed ID: 9921700 [TBL] [Abstract][Full Text] [Related]
35. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. Barbosa L; Berk M; Vorster M J Clin Psychiatry; 2003 Apr; 64(4):403-7. PubMed ID: 12716240 [TBL] [Abstract][Full Text] [Related]
36. A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression. Fang Y; Yuan C; Xu Y; Chen J; Wu Z; Cao L; Yi Z; Hong W; Wang Y; Jiang K; Cui X; Calabrese JR; Gao K; J Clin Psychopharmacol; 2011 Oct; 31(5):638-42. PubMed ID: 21869688 [TBL] [Abstract][Full Text] [Related]
37. Antiobsessional effect of risperidone add-on treatment in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder may be dose-dependent. Ramasubbu R Arch Gen Psychiatry; 2002 May; 59(5):472; author reply 472-3. PubMed ID: 11982460 [No Abstract] [Full Text] [Related]
38. Gynecomastia with risperidone-fluoxetine combination. Benazzi F Pharmacopsychiatry; 1999 Jan; 32(1):41. PubMed ID: 10071182 [TBL] [Abstract][Full Text] [Related]
39. [Clinical features of patients with obsessive-compulsive disorder showing different pharmacological responses]. Sumitani S; Ueno S; Ishimoto Y; Taniguchi T; Tomotake M; Motoki I; Yamauchi K; Ohmori T Seishin Shinkeigaku Zasshi; 2006; 108(12):1282-92. PubMed ID: 17334085 [TBL] [Abstract][Full Text] [Related]